Amjad H Talukder
Overview
Explore the profile of Amjad H Talukder including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
953
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sonnemann H, Pazdrak B, Nassif B, Sun Y, Elzohary L, Talukder A, et al.
Front Oncol
. 2024 Jun;
14:1403052.
PMID: 38912065
Introduction: Vestigial-like 1 (VGLL1) is a co-transcriptional activator that binds to TEA domain-containing transcription factors (TEADs). Its expression is upregulated in a variety of aggressive cancer types, including pancreatic and...
2.
Jackson K, Antunes D, Talukder A, Maleki A, Amagai K, Salmon A, et al.
PNAS Nexus
. 2022 Aug;
1(3):pgac124.
PMID: 36003074
Human leukocyte antigen class I (HLA-I) molecules bind and present peptides at the cell surface to facilitate the induction of appropriate CD8+ T cell-mediated immune responses to pathogen- and self-derived...
3.
Sun Y, Li F, Sonnemann H, Jackson K, Talukder A, Katailiha A, et al.
Cells
. 2021 Sep;
10(9).
PMID: 34572028
Engineered T cell receptor T (TCR-T) cell therapy has facilitated the generation of increasingly reliable tumor antigen-specific adaptable cellular products for the treatment of human cancer. TCR-T cell therapies were...
4.
Li F, Deng L, Jackson K, Talukder A, Katailiha A, Bradley S, et al.
J Immunother Cancer
. 2021 Jul;
9(7).
PMID: 34244308
Background: Neoantigen (NeoAg) peptides displayed at the tumor cell surface by human leukocyte antigen molecules show exquisite tumor specificity and can elicit T cell mediated tumor rejection. However, few NeoAgs...
5.
Bradley S, Talukder A, Lai I, Davis R, Alvarez H, Tiriac H, et al.
Nat Commun
. 2020 Oct;
11(1):5332.
PMID: 33087697
Cytotoxic T lymphocyte (CTL)-based cancer immunotherapies have shown great promise for inducing clinical regressions by targeting tumor-associated antigens (TAA). To expand the TAA landscape of pancreatic ductal adenocarcinoma (PDAC), we...
6.
Huang L, Malu S, McKenzie J, Andrews M, Talukder A, Tieu T, et al.
Clin Cancer Res
. 2018 Mar;
24(14):3366-3376.
PMID: 29496759
Cancer immunotherapy has shown promising clinical outcomes in many patients. However, some patients still fail to respond, and new strategies are needed to overcome resistance. The purpose of this study...
7.
Mbofung R, McKenzie J, Malu S, Zhang M, Peng W, Liu C, et al.
Nat Commun
. 2017 Sep;
8(1):451.
PMID: 28878208
T-cell-based immunotherapies are promising treatments for cancer patients. Although durable responses can be achieved in some patients, many patients fail to respond to these therapies, underscoring the need for improvement...
8.
Park J, Talukder A, Lim S, Kim K, Pan K, Melendez B, et al.
Cancer Immunol Res
. 2017 Jun;
5(8):618-629.
PMID: 28630054
Cytotoxic T lymphocyte (CTL)-based immunotherapies have had remarkable success at generating objective clinical responses in patients with advanced metastatic melanoma. Although the melanocyte differentiation antigens (MDA) MART-1, PMEL, and tyrosinase...
9.
Alatrash G, Garber H, Zhang M, Sukhumalchandra P, Qiu Y, Jakher H, et al.
Leukemia
. 2016 Aug;
31(1):234-237.
PMID: 27573556
No abstract available.
10.
Kim T, Hong S, Talukder A, Pascual V, Liu Y
Eur J Immunol
. 2015 Dec;
46(3):712-24.
PMID: 26648480
Toll-like receptors (TLRs) are playing important roles in stimulating the innate immune response and intensifying adaptive immune response against invading pathogens. Appropriate regulation of TLR activation is important to maintain...